RxDoctor Payments DataLook up a doctor →

Jennifer Jacks, MD

Dermatology · Pine Bluff, ARNPI 1699948901

Payments from drug & device makers

$20,508in general payments, 2019–2025

Across 540 payments — averaging $37.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$10K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novartis$1K
  • Johnson & Johnson$948
  • Sanofi$935
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$9,10044%
  • Travel & lodging$7153%
  • Food & beverage$10,36551%
  • Education$3282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,508 in reported general payments places this provider in the 85th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$639,622
Medicare patients
2,495
Services billed
10,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa49$1,012,983
Dupixent PenDupilumab110$402,963
Humira(Cf) PenAdalimumab45$394,105
Taltz AutoinjectorIxekizumab37$240,973
OtezlaApremilast48$234,383
Dupixent SyringeDupilumab33$121,355
Cosentyx Unoready PenSecukinumab11$111,698
Enbrel SureclickEtanercept13$97,579
Cosentyx Sensoready (2 Pens)Secukinumab13$96,808
RinvoqUpadacitinib15$96,124
OpzeluraRuxolitinib Phosphate23$46,472
Tacrolimus216$26,250
ZoryveRoflumilast22$19,053
Clobetasol Propionate224$11,224
Acitretin21$10,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$211$234,38348 claims
AbbVieRinvoq$2,284$96,12415 claims
Incyte CorporationOpzelura$218$46,47223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →